Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTABAX vs FLAGYL I.V.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
FDA-approved for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes in patients aged 9 months and older
Intra-abdominal infections (e.g., peritonitis, abscess),Pelvic inflammatory disease,Bacterial vaginosis,Surgical prophylaxis,Anaerobic infections (e.g., Clostridium, Bacteroides),Off-label: Helicobacter pylori eradication, rosacea, Crohn's disease
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
Retapamulin undergoes hepatic metabolism primarily via cytochrome P450 (CYP) isoenzymes, including CYP3A4, and is excreted in feces and urine.
Hepatic metabolism via oxidation and glucuronidation; major metabolites: hydroxy metabolite (active) and acetic acid metabolite; CYP450 involvement primarily CYP2A6 and CYP3A4.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
Retapamulin is approximately 94% bound to human plasma proteins, primarily albumin.
Less than 20%, primarily bound to albumin.
Volume of distribution after IV administration is approximately 3.1 L/kg, indicating extensive tissue distribution.
0.5-0.8 L/kg; indicates extensive tissue distribution, including CNS, bone, and abscesses.
Systemic bioavailability after topical application is low and highly variable, with mean values <2% in adults.
Intravenous: 100%.
No dose adjustment required for renal impairment as systemic absorption is negligible.
No dose adjustment for Cr Cl >10 m L/min. For Cr Cl <10 m L/min, extend interval to every 12 hours. For hemodialysis, administer dose post-dialysis.
No dose adjustment required for hepatic impairment as systemic absorption is negligible.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75%.
Children 9 months and older: Apply 1% ointment to affected area twice daily for 5 days. Maximum treatment area 100 cm². For children under 9 months: safety and efficacy not established.
Loading dose: 15 mg/kg IV. Maintenance: 7.5 mg/kg IV every 6 hours. Maximum single dose: 750 mg.
No specific dose adjustment required. Use same as adult dosing due to minimal systemic absorption.
Monitor renal function; adjust dose based on Cr Cl. No specific age-related dose reduction.
No black box warnings.
Carcinogenicity has been observed in chronic animal studies; avoid chronic use unless necessary.
Not for use on mucous membranes (e.g., eyes, mouth, vagina).,May cause application site reactions (e.g., pruritus, erythema, pain).,Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including retapamulin.,Prolonged use may result in overgrowth of nonsusceptible organisms.
Peripheral neuropathy and central nervous system toxicity (e.g., seizures, encephalopathy) with prolonged use; discontinue if neurological symptoms appear; use with caution in hepatic impairment; may cause disulfiram-like reaction with alcohol.
Hypersensitivity to retapamulin or any component of the formulation.
Hypersensitivity to metronidazole or nitroimidazoles; first trimester of pregnancy; concomitant use with disulfiram or alcohol.
None known. Topical application with negligible systemic absorption; no dietary restrictions.
Avoid alcohol and any products containing ethanol (e.g., cough syrups, mouthwash) during therapy and for at least 48 hours after completion. No specific food restrictions.
No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 times MRHD) showed no fetal harm. However, systemic absorption after topical application is minimal, so fetal exposure is negligible. Risk cannot be ruled out; classify as pregnancy category B.
Flagyl I. V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Second and third trimesters: Use only if clearly needed; no documented fetal toxicity at usual doses.
Not known if retapamulin is excreted in human milk. Systemic absorption is negligible after topical use, so risk to infant is likely low. M/P ratio not determined. Caution if applied to breast area to avoid infant ingestion.
Metronidazole is excreted in breast milk; M/P ratio approximately 0.9-1.0. Peak milk concentration 2-4 hours after dose. Breastfeeding not recommended during therapy and for 24 hours after the last dose due to potential carcinogenicity and adverse effects in infant.
No dose adjustment needed. Pharmacokinetics unchanged as systemic absorption is minimal (<1%) and not affected by pregnancy. Standard dosing: apply thin layer to affected area twice daily for 5 days.
No specific dose adjustments required in pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may slightly reduce serum levels but not necessitate dose modification. Use standard adult dosing with caution in severe hepatic impairment.
Retapamulin (Altabax) is a topical pleuromutilin antibiotic indicated for impetigo due to S. aureus or S. pyogenes. Apply to lesions twice daily for 5 days. Avoid contact with eyes, mouth, or mucous membranes. No systemic absorption significant; safe for use in children ≥9 months. Do not use on open wounds or burns. Monitor for local irritation; discontinue if hypersensitivity occurs.
FLAGYL I. V. (metronidazole) is a nitroimidazole antibiotic with potent anaerobic coverage. It is the drug of choice for Clostridioides difficile infection, but oral vancomycin is preferred for severe cases. IV formulation is used when oral route is not feasible. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). Metronidazole can prolong QT interval; use caution with other QT-prolonging drugs. It is compatible with most IV solutions but avoid mixing with calcium-containing solutions.
Apply a thin layer to the affected area twice daily for 5 days, even if symptoms improve.,Wash hands before and after application unless treating hand lesions.,Do not cover the area with bandages unless instructed by your doctor.,Avoid getting the ointment in your eyes, nose, mouth, or on vaginal area.,Stop use and inform your doctor if you develop severe irritation, redness, or swelling.,Store at room temperature away from heat and moisture.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, headache, and flushing.,Inform your doctor if you experience numbness or tingling in your hands or feet, as this may indicate nerve damage.,Report any new or worsening symptoms, especially if you have liver disease or are on blood thinners like warfarin (metronidazole can increase INR).,Do not take this medication if you are pregnant without consulting your doctor, especially in the first trimester.,Shake the IV bag gently before use; do not use if the solution is cloudy or contains particles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTABAX vs FLAGYL I.V., answered by our medical review team.
ALTABAX is a Topical Antibiotic that works by Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.. FLAGYL I.V. is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTABAX and FLAGYL I.V. depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTABAX is: 1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².. The standard adult dose of FLAGYL I.V. is: 500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTABAX and FLAGYL I.V. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTABAX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 time. FLAGYL I.V. is classified as Category C. Flagyl I.V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.